While Lynozyfic was granted accelerated approval based on response rate in the LINKER-MM1 trial, continued approval may depend upon verification and description of clinical benefit in a confirmatory trial, the company said.
Marketbeat.com provides numerous tools for investors, including the List of Cheap Dividend Stocks, a treasure trove of value-plays for income investors.
While most corners of the market were deep in the red, a few have performed well. Let's take a look at the ETFs that have been the quarter’s star performers, as they could also be winners next quarter if the current trends continue.
